Novel Targets and New Potential: Developments in the Treatment of Inflammation in Chronic Kidney Disease

Overview

Journal Expert Opin Investig Drugs

Specialty Pharmacology

Date 2008 Mar 28

PMID 18363512

Citations 14

Authors

Csaba P Kovesdy

Kamyar Kalantar-Zadeh

Affiliations

Soon will be listed here.

Abstract

Background: Patients with chronic kidney disease (CKD) of all stages experience extremely high mortality, with cardiovascular causes accounting for about half of all their deaths. Traditional risk factors such as hypertension, hypercholesterolemia and diabetes mellitus cannot explain the excessively high cardiovascular mortality in CKD. Chronic inflammation is one of the novel risk factors that appear to contribute to the increased mortality seen in patients with CKD. Therapeutic interventions targeting chronic inflammation in CKD may lead to improved outcomes.

Objectives: To describe the role of inflammation in CKD and to review anti-inflammatory pharmacologic therapies that could have a role in its therapy.

Methods: A review of the literature was carried out and expert opinion expressed.

Results/conclusion: Inflammation is a common and significant problem in CKD. There are currently no approved pharmacologic anti-inflammatory therapies in CKD but several agents are being studied in early clinical trials, while others could become viable alternatives in the future.

Citing Articles

Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease.

Lee H, Fessler M, Qu P, Heymann J, Kopp J BMC Nephrol. 2020; 21(1):270.

PMID: 32660446 PMC: 7358194. DOI: 10.1186/s12882-020-01921-7.

Medical and Periodontal Clinical Parameters in Patients at Different Levels of Chronic Renal Failure.

Perozini C, Ruivo G, Ricardo L, Pavesi L, Kim Y, Pallos D Int J Dent. 2017; 2017:9858073.

PMID: 28473854 PMC: 5394392. DOI: 10.1155/2017/9858073.

Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.

Kovesdy C, Quarles L Nephrol Dial Transplant. 2013; 28(9):2228-36.

PMID: 23625971 PMC: 3769978. DOI: 10.1093/ndt/gft065.

Let them eat during dialysis: an overlooked opportunity to improve outcomes in maintenance hemodialysis patients.

Kalantar-Zadeh K, Ikizler T J Ren Nutr. 2013; 23(3):157-63.

PMID: 23313434 PMC: 3632653. DOI: 10.1053/j.jrn.2012.11.001.

A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by α5β1 integrin in kidney mesangial cells.

Gooz P, Dang Y, Higashiyama S, Twal W, Haycraft C, Gooz M PLoS One. 2012; 7(3):e33350.

PMID: 22413019 PMC: 3297637. DOI: 10.1371/journal.pone.0033350.

References

Quattrocchi E, Dallman M, Feldmann M . Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. 2000; 43(8):1688-97. DOI: 10.1002/1529-0131(200008)43:8<1688::AID-ANR4>3.0.CO;2-C. View

Kaysen G, Dubin J, Muller H, Mitch W, Rosales L, Levin N . Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002; 61(6):2240-9. DOI: 10.1046/j.1523-1755.2002.00076.x. View

Jamison R, Hartigan P, Kaufman J, Goldfarb D, Warren S, Guarino P . Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298(10):1163-70. DOI: 10.1001/jama.298.10.1163. View

Jialal I, Stein D, Balis D, Grundy S, Adams-Huet B, Devaraj S . Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103(15):1933-5. DOI: 10.1161/01.cir.103.15.1933. View

TYRRELL D, Horne A, Holme K, Preuss J, Page C . Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol. 1999; 46:151-208. DOI: 10.1016/s1054-3589(08)60471-8. View

Sidhu J, Cowan D, Kaski J . The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003; 42(10):1757-63. DOI: 10.1016/j.jacc.2003.04.001. View

Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S . IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant. 2002; 17(11):1964-70. DOI: 10.1093/ndt/17.11.1964. View

Yang B, Baughman S, Sullivan J . Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003; 74(1):85-94. DOI: 10.1016/S0009-9236(03)00094-8. View

Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12):1399-402. DOI: 10.1038/82219. View

10.

Eknoyan G, Beck G, Cheung A, Daugirdas J, Greene T, Kusek J . Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010-9. DOI: 10.1056/NEJMoa021583. View

11.

Nadra I, Mason J, Philippidis P, Florey O, Smythe C, McCarthy G . Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?. Circ Res. 2005; 96(12):1248-56. DOI: 10.1161/01.RES.0000171451.88616.c2. View

12.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

13.

Su C, Wen X, Bailey S, Jiang W, Rangwala S, Keilbaugh S . A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999; 104(4):383-9. PMC: 408529. DOI: 10.1172/JCI7145. View

14.

Kamar N, Faguer S, Esposito L, Guitard J, Nogier M, Durand D . Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol. 2007; 67(4):250-4. DOI: 10.5414/cnp67250. View

15.

Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A . Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356(9237):1213-8. DOI: 10.1016/s0140-6736(00)02783-5. View

16.

Baeuerle P, Henkel T . Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12:141-79. DOI: 10.1146/annurev.iy.12.040194.001041. View

17.

Yang C, Hsu S, Wu M, Hsu S, Chien C . Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006; 69(4):706-14. DOI: 10.1038/sj.ki.5000109. View

18.

Arend W . Interleukin-1 receptor antagonist. Adv Immunol. 1993; 54:167-227. DOI: 10.1016/s0065-2776(08)60535-0. View

19.

Smith R, Chin J, Sam L, Justen J . Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum. 1991; 34(1):78-83. DOI: 10.1002/art.1780340112. View

20.

Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M . Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005; 32(3):469-76. View